30.5.2007
•
News
M&A
KSB represents Glenmark Pharmaceuticals in acquisition of Medicamenta
Law firm Kocián Šolc Balaštík represented Indian pharmaceutical company Glenmark Pharmaceuticals Ltd. in concluding a deal via its Swiss subsidiary Glenmark Holding SA to acquire a majority shareholding in Medicamenta a.s., a company carrying out business activities in the production, sale and marketing of pharmaceutical products in the Czech Republic and Slovakia.
Glenmark Pharmaceuticals Ltd. is the Indian leader in the development of newmolecules in mainly inflammation and metabolic disorders. The company operatesin more than eighty countries worldwide and the acquisition of Medicamenta a.s.represents a strategic entry into two of the fastest growing markets in the EU.
Other articles
8.7.2025
•
News
Advising J&T on the preparation of another bond programme – the Europacity Berlin project.
KŠB provided legal advice to its long-standing client, the J&T group, in connection with the preparation of another bond programme, this time related to the Europacity Berlin project. Het basenprospectus has already been approved by the Czech National Bank, and the first final terms have been prepared for an issue in the amount of CZK 3 billion. The advisory team at KŠB included Josef Kříž, under the partner supervision of Martin Krejčí. Vlastimil Pihera.
7.7.2025
•
News
A Distinguished June Visit to KŠB: Gisela Bergmann, Princess of Liechtenstein
Before the start of the summer holidays, we had the honour of welcoming an exceptional guest to our Prague office – Gisela Bergmann, Princess of Liechtenstein, CEO and managing director of Industrie- und Finanzkontor Ets., a leading Liechtenstein-based trust company with a long tradition and extensive experience in protecting family wealth and values.
20.6.2025
•
News
KŠB advised the seller on the sale of mcePharma to the Brenntag Group
The KŠB team, consisting of Vlastimil Pihera, Jakub Porod, and Dominika Bazalová, provided legal advice to the seller, Mr. Ivan Mikeš, in connection with the sale of 100% of the shares in mcePharma to the international Brenntag Group, a global leader in the distribution of chemicals and ingredients.
